Portage Biotech Inc (PRTG) Stock
PRTG is no longer traded. Portage Biotech was delisted from the Nasdaq in November 2025.
Prices on this page are historical; the last trade was November 5, 2025 at $4.70.
Portage Biotech stock price history
PRTG final trading statistics
- Final close
- $4.70
- Final trading day
- Nov 5, 2025
- Market cap at delisting
- $10.71M
- Shares outstanding
- 2.28M
- Final 52-week range
- $2.95 – $15.82
- Avg. volume (final 3 mo.)
- 823,644
- All-time high (split-adj.)
- $136500.06 · Nov 1995
- All-time low (split-adj.)
- $0.20 · Nov 2019
- Return since IPO
- -100.0%
- Beta
- 0.64
- Book value / share
- -$0.07
- Price / book
- -63.51
Portage Biotech annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $0.00 | -$6.8M | — |
| FY2024 | $0.00 | -$75.3M | -$24.81 |
| FY2023 | $0.00 | -$104.6M | -$5.99 |
| FY2022 | $0.00 | -$16.9M | -$1.29 |
| FY2021 | $0.00 | -$15.8M | -$1.23 |
Last five fiscal years reported before the delisting; fiscal year ending March. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Portage Biotech Inc
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials; and PORT-7, a potent and selective antagonist of the adenosine A2B receptor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Portage Biotech stock FAQ
What happened to Portage Biotech stock?
Portage Biotech stock was delisted from the Nasdaq. Its final close was $4.70 on November 5, 2025.
Is PRTG stock still trading?
No. PRTG was delisted from the Nasdaq in November 2025 and no longer trades on a U.S. exchange.
What was the last price of PRTG stock?
PRTG closed at $4.70 on its final trading day, November 5, 2025, for a market value of about $10.71M.
What were Portage Biotech's revenue and earnings in its last full fiscal year?
Portage Biotech reported revenue of $0.00 and net income of -$6.8M in fiscal 2025, its last full year as a public company.
When did Portage Biotech go public?
Portage Biotech Inc stock began trading on February 25, 2021.